Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)

被引:2
|
作者
Kamiya, Koji [1 ]
Saeki, Hidehisa [2 ]
Tokura, Yoshiki [3 ,4 ]
Yoshihara, Shigemi [5 ]
Sugai, Junichi [6 ]
Ohtsuki, Mamitaro [1 ]
机构
[1] Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Nippon Med Sch, Dept Dermatol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
[3] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[4] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[5] Dokkyo Med Univ, Dept Pediat, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[6] Sugai Dermatol Parkside Clin, 6-7-7 Motoimaizumi, Utsunomiya, Tochigi 3210954, Japan
关键词
atopic dermatitis; pediatric; proactive therapy; rank-down therapy; topical corticosteroids; FLUTICASONE PROPIONATE CREAM; DOUBLE-BLIND; GUIDELINES; MANAGEMENT; RELAPSE; EMOLLIENT; CHILDREN; MODERATE; RISK; 0.05-PERCENT;
D O I
10.3390/jcm11216477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy, n = 24; rank-down therapy, n = 25). During maintenance treatment, the relapse rate was 8.33% in the proactive therapy group and 20.0% in the rank-down therapy group (p = 0.0859). The mean (+/- standard deviation) itching score on a numerical rating scale in the rank-down therapy group increased significantly from 2.5 +/- 1.9 to 3.6 +/- 2.6 (p = 0.0438). Adverse events occurred in 2 patients receiving proactive therapy and 3 patients receiving rank-down therapy. Proactive therapy appears to be as safe as rank-down therapy and may be more effective for itch in pediatric AD in remission.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Proactive Management in Pediatric Subjects with Moderate to Severe Atopic Dermatitis
    Fukuie, Tatsuki
    Nomura, Ichiro
    Narita, Masami
    Suzuki, Tsukasa
    Tajima, Iwao
    Natsume, Osamu
    Taguchi, Tomohide
    Ogata, Tsutomu
    Tokura, Yoshiki
    Matsumoto, Kenji
    Ohya, Yukihiro
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB101 - AB101
  • [2] Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
    Mori, Masaaki
    Hara, Takuma
    Kikuchi, Masako
    Shimizu, Hiroyuki
    Miyamoto, Tomoyuki
    Iwashima, Satoru
    Oonishi, Tatsuya
    Hashimoto, Kunio
    Kobayashi, Norimoto
    Waki, Kenji
    Suzuki, Yasuo
    Otsubo, Yoshikazu
    Yamada, Hiroshi
    Ishikawa, Chikao
    Kato, Taichi
    Fuse, Shigeto
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [3] Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
    Masaaki Mori
    Takuma Hara
    Masako Kikuchi
    Hiroyuki Shimizu
    Tomoyuki Miyamoto
    Satoru Iwashima
    Tatsuya Oonishi
    Kunio Hashimoto
    Norimoto Kobayashi
    Kenji Waki
    Yasuo Suzuki
    Yoshikazu Otsubo
    Hiroshi Yamada
    Chikao Ishikawa
    Taichi Kato
    Shigeto Fuse
    [J]. Scientific Reports, 8
  • [4] Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
    Tao, Tao
    Zhang, Yi
    Zhu, Yu-Chen
    Fu, Jia-Rong
    Wang, Yu-Ying
    Cai, Jie
    Ma, Jing-Yu
    Xu, Yu
    Gao, Yi-Ning
    Sun, Yun
    Fan, WuQiang
    Liu, Wei
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (03): : E1420 - E1432
  • [5] An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis
    Mudaliyar, Vinodhini R.
    Pathak, Asha
    Dixit, Alok
    Kumar, Sweta S.
    [J]. DERMATOLOGY PRACTICAL & CONCEPTUAL, 2020, 10 (04):
  • [6] INTERMITTENT PROACTIVE MAINTENANCE TREATMENT WITH 0.03% TACROLIMUS OINTMENT IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY
    Liu, Lingling
    Zhu, Xuejun
    Zhao, Zuotao
    Wang, Shan
    Ma, Lin
    Gu, Heng
    Wang, Hua
    Chen, Jinping
    Yao, Zhirong
    Chen, Ji
    [J]. JOURNAL OF DERMATOLOGY, 2014, 41 : 10 - 10
  • [7] Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study
    Lee, Kyung-Hee
    Kang, Jung-Hun
    Oh, Ho-Suk
    Choi, Moon-Ki
    Shim, Byoung-Yong
    Eum, Young-Jun
    Park, Hye-Jeong
    Kang, Jin-Hyong
    [J]. PAIN RESEARCH & MANAGEMENT, 2017, 2017
  • [8] Comparing emollient use with topical luliconazole (azole) in the maintenance of remission of chronic and recurrent dermatophytosis. An open-label, randomized prospective active-controlled non-inferiority study
    Pathania, Yashdeep Singh
    Katoch, C. D. S.
    Kumar, Ashok
    [J]. MYCOSES, 2024, 67 (01)
  • [9] Open-label, parallel-group, multicenter, randomized study of cefprozil versus erythromycin in children with group A streptococcal pharyngitis/tonsillitis
    Brook, I
    Aronovitz, GH
    Pichichero, ME
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (11) : 1889 - 1900
  • [10] Early enhanced treatment for infant atopic dermatitis prevents food allergy: A multicenter, parallel-group, open-label, assessor-blind, randomized controlled trial (PACI study)
    Yamamoto-Hanada, K.
    Kobayashi, T.
    Mikami, M.
    Williams, H.
    Saito-Abe, M.
    Sato, M.
    Miyaji, Y.
    Ishikawa, F.
    Irahara, M.
    Tsuchiya, K.
    Tamagawa-Mineoka, R.
    Takaoka, Y.
    Takemura, Y.
    Sato, S.
    Wakiguchi, H.
    Hoshi, M.
    Natsume, O.
    Yamaide, F.
    Seike, M.
    Kabashima, S.
    Yoshida, K.
    Inuzuka, Y.
    Nishimura, K.
    Toyokuni, K.
    Ogita, H.
    Kiguchi, T.
    Saito, J.
    Morimoto, M.
    Masuda, K.
    Katoh, N.
    Hosoi, H.
    Kameda, M.
    Shigekawa, A.
    Yamasaki, K.
    Nagai, M.
    Ebisawa, M.
    Asaumi, T.
    Itonaga, T.
    Hasegawa, S.
    Yasudo, H.
    Nagao, M.
    Fujisawa, T.
    Yasuoka, R.
    Fujiyama, T.
    Shimojo, N.
    Nakano, T.
    Mori, Y.
    Kondo, Y.
    Kawaguchi, T.
    Futamura, M.
    [J]. ALLERGY, 2023, 78 : 96 - 96